New Home Test Could Help in Colon Cancer Battle

Starting Monday, millions of people who have avoided colon cancer screening can get a new home test that's noninvasive and doesn't require the icky preparation most other methods do.

The test is the first to look for cancer-related DNA in stool. But deciding whether to get it is a more complex choice than ads for "the breakthrough test ... that's as easy as going to the bathroom" make it seem.

On one hand, the test could greatly boost screening for a deadly disease that too few people get checked for now. On the other hand, it could lure people away from colonoscopies and other tests that, unlike the new one, have been shown to save lives. It might even do both.

The test was approved by the Food and Drug Administration in August and will be offered by prescription at the Mayo Clinic in Minnesota, where it was developed, starting Monday, with Medicare reimbursement. It has been sold through a website and private practice doctors since its approval for people willing to pay for it themselves. It's called Cologuard and is sold by Exact Sciences Corp. of Madison, Wisconsin. Mayo Clinic and one of its doctors get royalties from the test.

Many current stool tests look for blood that could suggest a tumor. Cologuard does this plus detects DNA that could be a sign of cancer or precancerous growths called polyps. People send a stool sample to a lab where it is tested.

The best measure of a screening test's worth is whether it lowers the risk of death from a disease, and it's too soon to know whether Cologuard will. The U.S. Preventive Services Task Force, which sets widely followed screening advice, has not yet considered it.

Colorectal cancer is the second leading cause of cancer deaths in the United States and the fourth worldwide. More than 143,000 new cases and 52,000 deaths from the disease are expected this year in the U.S. alone. Only about 60 percent of people recommended to get screened do so now.

This story has been updated to reflect the following: In a story Oct. 26 about Cologuard, a new DNA test for colon cancer screening, The Associated Press reported erroneously that the test was approved in September and was not yet available nationwide. The test was approved in August and has been available through the Cologuard website and private practice physicians for people willing to pay for it themselves, not just starting Monday at the Mayo Clinic with Medicare reimbursement.

IN-DEPTH

• FDA Approves DNA-Based Test for Colon Cancer
• New Stool Test Better at Detecting Cancer

— The Associated Press

For Subscribers

FOR SUBSCRIBERSA sluggish Congress punts a long list of tasks until after the election

FOR SUBSCRIBERSIt’s rarely been harder for people to find new jobs

FOR SUBSCRIBERS‘Some of the medication has worn off’: Witness recalls failed Tennessee execution of Christa Pike

FOR SUBSCRIBERS‘Couldn’t let all of them die’: Hero Indian pilot attacked midair speaks for first time

FOR SUBSCRIBERSHow Trump’s homelessness crackdown became a sweeping retreat from disability rights

FOR SUBSCRIBERSCornell rape allegation pushes embattled New York prosecutor into national spotlight

FOR SUBSCRIBERSJudge guts noncitizen voting law used in Trump administration’s election push

FOR SUBSCRIBERSTrump to campaign in at least 17 states ahead of the midterms

FOR SUBSCRIBERSThe prosecutor at the center of the Cornell maelstrom

FOR SUBSCRIBERSCBP leaders cut out of Trump ad buy decision

FOR SUBSCRIBERSAmerican passenger drafted goodbye texts to her family as Flydubai plane plummeted

FOR SUBSCRIBERSAbdul El-Sayed tries to woo MAHA voters as Democrats seek inroads with RFK’s supporters

FOR SUBSCRIBERSKratom-like substances are popping up in a typically benign supplement

FOR SUBSCRIBERSGOP super PAC increases its spending for Sen. Jon Husted in tough Ohio race

FOR SUBSCRIBERSRecords reveal tumultuous marriage between slain New York Times executive and wife

For Subscribers

FOR SUBSCRIBERSA sluggish Congress punts a long list of tasks until after the election

FOR SUBSCRIBERSIt’s rarely been harder for people to find new jobs

FOR SUBSCRIBERS‘Some of the medication has worn off’: Witness recalls failed Tennessee execution of Christa Pike

FOR SUBSCRIBERS‘Couldn’t let all of them die’: Hero Indian pilot attacked midair speaks for first time

FOR SUBSCRIBERSHow Trump’s homelessness crackdown became a sweeping retreat from disability rights

FOR SUBSCRIBERSCornell rape allegation pushes embattled New York prosecutor into national spotlight

FOR SUBSCRIBERSJudge guts noncitizen voting law used in Trump administration’s election push

FOR SUBSCRIBERSTrump to campaign in at least 17 states ahead of the midterms

FOR SUBSCRIBERSThe prosecutor at the center of the Cornell maelstrom

FOR SUBSCRIBERSCBP leaders cut out of Trump ad buy decision

FOR SUBSCRIBERSAmerican passenger drafted goodbye texts to her family as Flydubai plane plummeted

FOR SUBSCRIBERSAbdul El-Sayed tries to woo MAHA voters as Democrats seek inroads with RFK’s supporters

FOR SUBSCRIBERSKratom-like substances are popping up in a typically benign supplement

FOR SUBSCRIBERSGOP super PAC increases its spending for Sen. Jon Husted in tough Ohio race

FOR SUBSCRIBERSRecords reveal tumultuous marriage between slain New York Times executive and wife